Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening
- PMID: 17062013
- DOI: 10.1111/j.1747-0285.2006.00430.x
Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening
Abstract
Glycogen synthase kinase-3 is a serine/threonine kinase that has attracted significant drug discovery attention in recent years. To investigate the identification of new potential glycogen synthase kinase-3 inhibitors, a pharmacophore mapping study was carried out using a set of 21 structurally diverse glycogen synthase kinase-3 inhibitors. A hypothesis containing four features: two hydrophobic, one hydrogen bond donor and another hydrogen bond acceptor was found to be the best from the 10 common feature hypotheses produced by HipHop module of Catalyst. The best hypothesis has a high cost of 156.592 and higher best fit values were obtained for the 21 inhibitors using this best hypothesis than the other HipHop hypotheses. The best hypothesis was then used to screen electronically the NCI2000 database. The hits obtained were docked into glycogen synthase kinase-3beta active site. A total of five novel potential leads were proposed after: (i) visual examination of how well they dock into the glycogen synthase kinase-3beta-binding site, (ii) comparative analysis of their FlexX, G-Score, PMF-Score, ChemScore and D-Scores values, (iii) comparison of their best fit value with the known inhibitors and (iv) examination of the how the hits retain interactions with the important amino acid residues of glycogen synthase kinase-3beta-binding site.
Similar articles
-
Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.Biophys Chem. 2007 Jul;128(2-3):165-75. doi: 10.1016/j.bpc.2007.04.001. Epub 2007 Apr 19. Biophys Chem. 2007. PMID: 17482749
-
The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.Chem Biol Drug Des. 2007 Mar;69(3):204-11. doi: 10.1111/j.1747-0285.2007.00488.x. Chem Biol Drug Des. 2007. PMID: 17441906
-
A common feature-based 3D-pharmacophore model generation and virtual screening: identification of potential PfDHFR inhibitors.J Enzyme Inhib Med Chem. 2010 Oct;25(5):635-45. doi: 10.3109/14756360903393817. J Enzyme Inhib Med Chem. 2010. PMID: 19995305
-
Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.Curr Opin Drug Discov Devel. 2008 Jul;11(4):533-43. Curr Opin Drug Discov Devel. 2008. PMID: 18600569 Review.
-
[A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].Yao Xue Xue Bao. 2007 Dec;42(12):1227-31. Yao Xue Xue Bao. 2007. PMID: 18338632 Review. Chinese.
Cited by
-
Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.J Comput Aided Mol Des. 2009 Feb;23(2):113-27. doi: 10.1007/s10822-008-9244-1. Epub 2008 Oct 7. J Comput Aided Mol Des. 2009. PMID: 18839067
-
Allosteric regulation of glycogen synthase kinase 3β: a theoretical study.Biochemistry. 2010 Dec 28;49(51):10890-901. doi: 10.1021/bi100822q. Epub 2010 Dec 3. Biochemistry. 2010. PMID: 21105670 Free PMC article.
-
Novel virtual screening approach for the discovery of human tyrosinase inhibitors.PLoS One. 2014 Nov 26;9(11):e112788. doi: 10.1371/journal.pone.0112788. eCollection 2014. PLoS One. 2014. PMID: 25426625 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources